HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced promising clinical data from investigator-sponsored studies of ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, FOLOTYN (pralatrexate injection), and belinostat, Spectrums novel histone deacetylase (HDAC) inhibitor. As reported in poster presentations at the recent 54th Annual Meeting of the American Society of Hematology (ASH), studies of ZEVALIN showed promising results in diverse settings and potential indications, including first-line consolidation in patients with diffuse large B-cell lymphoma (DLBCL); treatment of elderly patients with non-Hodgkins lymphoma (NHL), and new drug combinations to treat follicular non-Hodgkins lymphoma (fNHL). In addition, preclinical in vivo research showed promising synergistic, anti-tumor activity of FOLOTYN, while a Phase 1 study demonstrated early evidence of activity of belinostat in combination therapy of patients, including those with relapsed or refractory acute leukemia. This years ASH meeting was another important conference for Spectrum, both because of the number of presentations 12 for ZEVALIN, 3 for FOLOTYN and 4 for belinostat and the high quality of the data, said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. Members of … Continue reading →

VILLA GUARDIA (COMO), Italy, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (GENT) (the "Company") today announced that additional data from ongoing trials of Defibrotide were presented this week at the 54th Annual Meeting and Exposition of the American Society of Hematology (ASH) held at the Georgia World Congress Center in Atlanta, Georgia. Dr. Paul Richardson, Clinical Director of the Dana-Farber Cancer Institute, Boston, MA (USA), reported in an oral presentation the updated results of a large prospective study on the use of Defibrotide in the treatment of Hepatic Veno-Occlusive Disease (VOD) in hematopoietic stem cell transplant patients, from the ongoing Treatment IND Expanded Access Protocol (abstract #738). The interim analysis was based on 333 patients with severe veno-occlusive disease (sVOD) and multi-organ failure (MOF), enrolled between December 2007 and September 2011 at 68 centers across the United States. 305 patients had undergone hematopoietic stem cell transplant (HSCT) and of those patients, 30% of patients achieved a complete response (CR) and 50% survived to day 100 (D+100). Additional findings were as follows: Dr. Richardson also presented a poster outlining the results from the treatment of chemotherapy-induced VOD in non-stem cell transplant (non-SCT) patients enrolled in the Treatment IND Expanded Access … Continue reading →